RANKL inhibition with denosumab decreases markers of bone and cartilage turnover in patients with rheumatoid arthritis.

被引：0
|
作者：
Lane, N. E.
Iannini, M.
Atkins, C.
Haraoui, B.
Zhou, L.
Tsuji, W.
Newmark, R.
机构：
[1] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA
[2] Carondelet Med Grp, Tucson, AZ USA
[3] Inst Rhumatol, Montreal, PQ, Canada
[4] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
ARTHRITIS AND RHEUMATISM | 2006年 / 54卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S225 / S226
页数：2
相关论文
共 50 条
  • [1] Inhibition of RANKL with denosumab reduces markers of bone and cartilage turnover in patients with rheumatoid arthritis
    Lane, N.
    Iannini, M.
    Atkins, C.
    Haraoui, B.
    Zhou, L.
    Tsuji, W.
    Newmark, R.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S17 - S18
  • [2] Hormone replacement therapy decreases markers of cartilage and bone metabolism in rheumatoid arthritis.
    d'Elia, HF
    Christgau, S
    Mattsson, L
    Saxne, T
    Ohlsson, C
    Nordborg, E
    Carlsten, H
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S396 - S396
  • [3] Inhibition of RANKL with denosumab decreases progression of bone erosions in patients with rheumatoid arthritis: MRI results at 6 months
    Cohen, S. B.
    Valen, P.
    Ritchlin, C.
    Schechtman, J.
    Peterfy, C.
    van der Heijde, D.
    Zhou, L.
    Newmark, R.
    Tsuji, W.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S15 - S16
  • [4] RANKL inhibition with denosumab increases bone mineral density in patients with rheumatoid arthritis
    Dore, R. K.
    Hurd, E.
    Palmer, W.
    Shergy, W.
    Zhou, L.
    Newmark, R.
    Tsuji, W.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S85 - S85
  • [5] Consistent Inhibition of Bone Destruction By Denosumab in Important Subgroups of Japanese Patients with Rheumatoid Arthritis.
    Ishiguro, Naoki
    Tanaka, Yoshiya
    Yamanaka, Hisashi
    Yoneda, Toshiyuki
    Ohira, Takeshi
    Okubo, Naoki
    Genant, Harry K.
    van der Heijde, Desiree
    Takeuchi, Tsutomu
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S831 - S832
  • [6] Denosumab increases bone mineral density in patients with rheumatoid arthritis.
    Dore, R.
    Hurd, E.
    Palmer, W.
    Shergy, W.
    Zhou, L.
    Newmark, R.
    Tsuji, W.
    Dore, Robin K.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S240 - S240
  • [7] Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates
    Tetsuya Kaneko
    Koichi Okamura
    Yukio Yonemoto
    Chisa Okura
    Takahito Suto
    Masahiro Tachibana
    Hideo Sakane
    Makoto Inoue
    Hirotaka Chikuda
    Journal of Experimental Orthopaedics, 6
  • [8] Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates
    Kaneko, Tetsuya
    Okamura, Koichi
    Yonemoto, Yukio
    Okura, Chisa
    Suto, Takahito
    Tachibana, Masahiro
    Sakane, Hideo
    Inoue, Makoto
    Chikuda, Hirotaka
    JOURNAL OF EXPERIMENTAL ORTHOPAEDICS, 2019, 6 (01)
  • [9] Effects of the anti-TNF-antibody infliximab on markers of bone turnover in patients with rheumatoid arthritis.
    Mueller, TJ
    Hermann, J
    Fahrleitner, A
    Yazdani-Biuki, B
    Dimai, HP
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S232 - S232
  • [10] Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis
    Chopin, F.
    Garnero, P.
    le Henanff, A.
    Debiais, F.
    Daragon, A.
    Roux, C.
    Sany, J.
    Wendling, D.
    Zarnitsky, C.
    Ravaud, P.
    Thomas, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (03) : 353 - 357
12345